Patient reported outcomes interfering with daily activities in prostate cancer patients receiving antineoplastic treatment

References

• Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21(7):1159–1164.
   PubMed Web of Science ®Google Scholar
• Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865–869.
   PubMed Web of Science ®Google Scholar
• Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22(17):3485–3490.
   PubMed Web of Science ®Google Scholar
• Pakhomov SV, Jacobsen SJ, Chute CG, et al. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care. 2008;14(8):530–539.
   PubMed Web of Science ®Google Scholar
• Basch E, Reeve BB, Mitchell SA, et al. Development of the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.
   PubMedGoogle Scholar
• Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624–1632.
   PubMedGoogle Scholar
• Kluetz PG, Chingos DT, Basch EM, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ B. 2016;35:67–73.
   PubMedGoogle Scholar
• Smith AW, Mitchell SA, De Aguiar C K, et al. News from the NIH: person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity. Transl Behav Med. 2016;6(3):470–474.
   PubMed Web of Science ®Google Scholar
• Baeksted C, Pappot H, Nissen A, et al. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) in Danish prostate cancer patients. J Patient Rep Outcomes. 2017;1(1):1.
   PubMedGoogle Scholar
• Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2004;25(6):535–552.
   PubMedGoogle Scholar
• Bruner DW, Bryan CJ, Aaronson N, et al. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-Sponsored Clinical Trials Networks. J Clin Oncol. 2007;25(32):5051–5057.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Gotay CC. Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions. J Clin Oncol. 2007;25(32):5063–5069.
   PubMed Web of Science ®Google Scholar
• Taarnhøj GA, Johansen C, Lindberg H, et al. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. Cancer Med. 2020;9(9):3078–3087.
   PubMed Web of Science ®Google Scholar
• Lipscomb J, Reeve BB, Clauser SB, et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol. 2007;25(32):5133–5140.
   PubMed Web of Science ®Google Scholar
• Martin C, Haaland B, Tward AE, et al. Describing the spectrum of patient reported outcomes after radical prostatectomy: providing information to improve patient counseling and shared decision making. J Urol. 2019;201(4):751–758.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Klink A, Prasad V. Real-world evidence – what does it really mean? JAMA Oncol. 2019;5(6):781.
   PubMed Web of Science ®Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence – what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297. [Internet]. Available from: http://www.nejm.org/doi/10.1056/NEJMsb1609216
   PubMed Web of Science ®Google Scholar
• Cella D, Hahn E, Jensen S, et al. Patient-reported outcomes in performance measurement. Research Triangle Park (NC): RTI Press; 2015.
   Google Scholar
• National Institute of Cancer. The PRO-CTCAE Measurement System [Internet]. Available from: https://healthcaredelivery.cancer.gov/pro-ctcae/measurement.html
   Google Scholar
• Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249–4255.
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Dangas G. Guidelines for patient-reported outcomes in clinical trial protocols. JAMA J Am Med Assoc. 2018;319(5):450.
   PubMed Web of Science ®Google Scholar
• Hamaker ME, Seynaeve C, Wymenga ANM, et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists’ Group. Breast. 2014.
   Google Scholar
• Ruiz J, Miller AA, Tooze JA, et al. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age. J Geriatr Oncol. 2019;10(1):P48–P54.
   PubMed Web of Science ®Google Scholar
• Aaldriks AA, van der Geest LGM, Giltay EJ, et al. Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. J Geriatr Oncol. 2013;4(3):126–218.
   Web of Science ®Google Scholar
• Lindahl-Jacobsen L, Hansen DG, Waehrens EE, et al. Performance of activities of daily living among hospitalized cancer patients. Scand J Occup Ther. 2015;22(2):137–146.
   PubMed Web of Science ®Google Scholar
• Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson D, Heinrich S, Helle SI, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–992.
   PubMed Web of Science ®Google Scholar
• Schougaard LMV, Mejdahl CT, Petersen KH, et al. Tele-patient-reported outcomes (telePRO) in clinical practice-effect of patient-initiated versus fixed interval telePRO based outpatient follow-up: study protocol for a pragmatic randomized controlled study. Qual Life Res. 20160;17:83.
   Google Scholar
• Holmstrom S, Naidoo S, Turnbull J, et al. Symptoms and impacts in metastatic castration-resistant prostate cancer: qualitative findings from patient and physician interviews. Patient. 2019;12(1):57–67.
   PubMedGoogle Scholar
• Elm V, Altman E, Egger DG, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573–577.
   Google Scholar
• Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA. J Clin Oncol. 2017;35(28):3189–3197.
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer - PROSELICA. J Clin Oncol. 2017;35(28):3198–3206.
   PubMed Web of Science ®Google Scholar
• Di Maio M, Basch E, Bryce J, et al. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol. 2016;13(5):319–325.
   PubMed Web of Science ®Google Scholar
• Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ. 2010;340(1):c2921–c2921.
   PubMedGoogle Scholar
• EMA. Reflection paper on the use of patient reported outcome (PRO) measures in oncology studies. European Medicines Agency Science Medicines Health. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-reflection-paper-use-patient-reported-outcome-pro-measures-oncology-studies_en.pdf
   Google Scholar
• EMA. The use of patient-reported outcome (PRO) measures in oncology studies [Internet]. Available from: https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf
   Google Scholar
• Chi KN, Protheroe A, Rodríguez-Antolín A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018;19(2):194–206.
   PubMed Web of Science ®Google Scholar
• Tombal B, Saad F, Penson D, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(4):556–569.
   PubMed Web of Science ®Google Scholar
• Cella D, Traina S, Li T, et al. Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. Ann Oncol off J Eur Soc Med Oncol. 2018;29(2):392–397.
   PubMed Web of Science ®Google Scholar
• Luo J, Graff JN. Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Res Rep Urol. 2016;8:217–224.
   PubMed Web of Science ®Google Scholar
• Thiery-Vuillemin A, Poulsen MH, Lagneau E, et al. Impact of abiraterone acetate plus prednisone or enzalutamide on patient-reported outcomes in patients with metastatic castration-resistant prostate cancer: final 12-mo analysis from the observational AQUARiUS study. Eur Urol. 2020;77(3):380–387.
   PubMed Web of Science ®Google Scholar
• Dueck AC, Scher HI, Bennett AV, et al. Assessment of adverse events from the patient perspective in a phase 3 metastatic castration-resistant prostate cancer clinical trial. JAMA Oncol. 2020;6(2):e193332.
   PubMed Web of Science ®Google Scholar
• Unger JM, Griffin K, Donaldson GW, et al. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes. 2017;2:27.
   PubMedGoogle Scholar
• Fendler WP, Reinhardt S, Ilhan H, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581–3590.
   PubMedGoogle Scholar
• Hilarius DL, Kloeg PH, Van Der Wall E, et al. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer. 2012;20(1):107–117.
   PubMed Web of Science ®Google Scholar
• Taarnhoj G, Lindberg H, Johansen C, et al. Quality of life in bladder cancer patients receiving chemotherapy: a real life experience. Qual Life Res. 2018;27:S124–S125.
   Web of Science ®Google Scholar
• Colloca G, Colloca P. Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need? Med Oncol. 2011;28(2):519–527.
   PubMed Web of Science ®Google Scholar
• Taarnhøj GA, Kennedy FR, Absolom KL, et al. Comparison of EORTC QLQ-C30 and PRO-CTCAETM Questionnaires on six symptom items. J Pain Symptom Manage. 2018;56(3):421–429.
   PubMed Web of Science ®Google Scholar
• Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Heal. 2007;10(Suppl 2):S125–S137.
   PubMed Web of Science ®Google Scholar
• Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–565.
   PubMed Web of Science ®Google Scholar
• Colloca G, Venturino A, Checcaglini F. Patient-reported outcomes after cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a systematic review. Cancer Treat Rev. 2010;36(6):501–506.
   PubMed Web of Science ®Google Scholar
• Clark MJ, Harris N, Griebsch I, et al. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union. Health Qual Life Outcomes. 2014;12:104.
   PubMed Web of Science ®Google Scholar
• Harrington SE, Smith TJ. The role of chemotherapy at the end of life: “when is enough, enough? JAMA J Am Med Assoc. 2008;299(22):2667.
   PubMed Web of Science ®Google Scholar
• PEBC’s Ovarian Oncology Guidelines Group. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2017;146(2):392–398.
   PubMed Web of Science ®Google Scholar
• Riikonen JM, Guyatt GH, Kilpeläinen TP, et al. Decision aids for prostate cancer screening choice: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(8):1072–1082.
   PubMed Web of Science ®Google Scholar
• Schougaard L, Hjollund N. AmbuFlex-experiences of PRO-based clinical decision-making. Qual Life Res. 2017;26(1):8.
   Web of Science ®Google Scholar